Verona Pharma (VRNA) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed ...

Verona Pharma (NASDAQ:VRNA)'s stock has reached an unprecedented peak, setting an all-time high at $56.49. This milestone underscores a remarkable period of growth for the $4.49 billion ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

This page features the latest news about the Verona Pharma ADR stock. Piper Sandler lifts Verona Pharma shares target citing high COPD drug approval odds On Tuesday, Piper Sandler exhibited confidence ...

Verona Pharma has blockbuster hopes for its recently approved drug for chronic obstructive pulmonary disorder (COPD), and preliminary sales figures for the drug suggest it is heading in the right ...

UK-based Verona Pharma has scored a new win with its chronic obstructive pulmonary disease (COPD) drug ensifenitrine, after a formulation delivered with an inhaler met its goals in a phase 2 trial.

After hours: January 31 at 7:50:01 PM EST Loading Chart for VRNA ...

Sanofi S.A. Part Cert-1.97% €8.03M ...

After hours: 31 January at 7:50:01 pm GMT-5 ...